CD105 is also known as Endoglin and it modulates cellular response to TGF-β1, involved in vascular development and remodeling. It is a type I integral membrane homodimer protein with subunits of 90 kD found on vascular endothelial cells, bone marrow stromal cells, and hematopoietic stem/progenitor cells.  CD105 is weakly expressed on stromal fibroblasts. It is also expressed on activated monocytes and tissue macrophages. Expression of CD105 is increased on activated endothelium in tissues undergoing angiogenesis, such as in tumors, or in cases of wound healing or dermal inflammation.  CD105 is a component of the TGF-β receptor system in human umbilical vein endothelial cells and binds TGF-β1 and β3 with high affinity but does not bind to TGF-β2.

This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.

*Data subject to review by the scientific team at ATS. See complete details here.

Anti-CD105-SAP eliminates cells expressing human CD105 (Endoglin). All other cells are left untouched.

To view protocol(s) for this and other products please visit: www.ATSbio.com/support/protocols

Advanced Targeting Systems(ATS)位于美国加州圣地亚哥， 成立于1994年。 公司发起人Douglas Lappi和Ronald Wiley博士在实验室开发出先进的分子神经外科学研究技术。ATS主要生产用于科研和药物研发的靶向试剂，公司在疼痛和药物转运的研究及临床治疗的两个产品已获专利保护。目前，产品包括靶向毒素 (可提供基底前脑胆碱能神经元、去甲肾上腺素能和肾上腺素能神经元、巨噬细胞和小胶质细胞的特异性损伤试剂等)、二抗生物素、神经元抗体、神经递质抗体、蛋白质和荧光结合物、免疫毒素对照等。